Lux Lung 7
Paz-Ares ESMO 2016
Drug Related AEs
Afatinib (n=160)
Gefitinib (n=159)
All Gr
Grade ≥3*
All Gr
Grade ≥3*
Any AE, n (%)
97.5
31.3
96.2
19.5
Diarrhoea
90.0
13.1
†
61.0
1.3
Rash/Acne‡
88.8
9.4
81.1
3.1
Stomatitis‡
64.4
4.4
23.9
-
Paronychia‡
56.3
1.9
17.6
0.6
Dry skin
32.5
-
37.1
-
Pruritus
23.1
-
22.6
-
Fatigue‡
20.6
5.6
14.5
-
ALT increased
9.4
-
23.9
8.2
†
AST increased
6.3
-
20.8
2.5
Low rates of treatment discontinuation due to drug-related AEs were observed in each arm (6% each)
Four cases of drug-related ILD were observed with gefitinib (three grade ≥3); none were observed with afatinib
